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INTRODUCTION
Minimal hepatic encephalopathy (MHE) is a state
of mental disturbance which cannot be diagnosed
clinically but there is impairment with psychometric
test.1,2,3 MHE can have a far-reaching impact on the
patient’s quality of life, and also increases the risk of
development of overt hepatic encephalopathy
(HE).4 MHE has difficulty being diagnosed because
of the psychometric test is not easy to be carried out.5,6
Psychometric hepatic encephalopathy score
(PHES) test has been used as the gold standard
measurement for diagnosing MHE. However, such
test is affected by age and education level.7 Gomez et
al found that the critical flicker frequency (CFF)
test has a good validation to the PHES test. CFF test
was easier, and less influenced by educational level of
patients.8 Study on precision of such test has been
conducted in Jakarta, and these tests have obtained
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ABSTRACT
Background: The dietary protein restriction that was commonly recommended to hepatic
encephalopathy (HE) patients, often leads to malnutrition, whereas malnutrition can deteriorate
cirrhosis prognosis. The aims of this study were to find out encephalopathy improvement that was
measured by critical flicker frequency (CFF) test and nutritional status by measuring prealbumin level
after L-Ornithine L-Aspartate (LOLA) treatment with adequate calories and protein intake in patients
with HE.
Method: Patients with liver cirrhosis who visited Cipto Mangunkusumo hospital on June-October
2009 was evaluated by CFF test using HEPAtonormTM device. Encephalopathy was defined when CFF <
39 Hz. Nutritional status was measured by the mid-arm muscle circumference (MAMC) and was stated as
malnutrition when the MAMC was below the 15th percentile. Patients had been treated by 3 x 6 mg LOLA
granules for 2 weeks, and adequate calories and protein intake with branched-chain amino acid (BCAAs)
substitution. The change of encephalopathy was evaluated by the CFF test and the nutritional status by
measuring prealbumin blood level.
Results: There were 17 patients with liver cirrhosis who fulfilled the inclusion criteria. The mean CFF
result increased from 34.1 ± 2.5 Hz to 36.5 ± 2.9 Hz after LOLA treatment with the adequate calories and
protein intake including BCAAs substitution, which was statistically significant (p < 0.001) compared to
before treatment. The prealbumin level also increased significantly compared before treatment, i.e. from
5.4 ± 2.1 mg/dL to 6.4 ± 2.6 mg/dL, p = 0.008.
Conclusion: HE patients with malnutrition could be given adequate calorie and protein with BCAAs
substitution to improve their nutritional status, and LOLA granules for the improvement of HE.
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good precision.9,10 
In liver cirrhosis, elevation of blood ammonia  
levels lead to increased number of peripheral  
benzodiazepines receptors (PBR), including the PBR  
in astrocytes and microglia in the brain. Furthermore,  
reactive oxygen species (ROS) also increased, followed  
by mitochondrial dysfunction, which resulted in the  
structure and function abnormalities in the brain  
astrocytes then lead into HE.11 Since HE is due to  
increased blood ammonia level, protein intake was  
restricted in the management of HE. However, this  
would lead to malnutrition, which worsens the outcome  
of liver cirrhosis.12,13 
Various studies have demonstrated that L-ornithine- 
L-aspartate (LOLA) can lower blood ammonia  
levels.14-18 LOLA stimulates the urea cycle and  
glutamine synthesis, which is an important mechanism  
in the detoxification of ammonia.19 With the efforts of  
LOLA, protein restriction is no longer needed to  
decrease blood ammonia levels. The European  
Society for Clinical Nutrition and Metabolism (ESPEN)  
recommended dietary of 35-40 kcal/kg/day and  
protein 1.2-1.5 g/kg/day for liver cirrhosis.12  
ESPEN also recommended the use of branched chain  
amino acids (BCAAs) to improve the nutritional  
status of patients with liver cirrhosis and  
malnutrition.12,20 
Based on those issues, it is necessary to do 
research to find out whether LOLA could improve 
MHE in liver cirrhosis with malnutrition, even 
with adequate calories and protein intake. 
The purposes of our study were: (1) To determine  
the improvement of CFF test; (2) Increasing of  
prealbumin level after intervention with LOLA and  




This study was conducted in Cipto Mangunkusumo  
hospital and Koja hospital between June-October 2009,  
with a pre-test post-test design. It aimed to know  
the CFF test and prealbumin levels before and after  
LOLA treatment and the BCAA substitution to the  
MHE. 
The diagnosis of liver cirrhosis was established 
histologically or based on the presence of at least two 
of the following: characteristic imaging features, 
oesophageal or gastric varices, ascites or increased 
international normalized ratio (INR) that could not 
be attributed to any other cause.21 
MHE was measured with HEPAtonormTM analyzer,  
CFF < 39 Hz was considered to have encephalo- 
pathy.5,6 Nutritional status assessed by mid-arm muscle  
circumference (MAMC). Patients were considered  
to be malnourished when MAMC was below the 15th 
percentile, according to Frisancho reference data 
(NHANES I and II).22,23 Prealbumin was taken to  
assess the nutritional status improvement, performed  
with nephelometric technique, with normal value of  
24.8-37.2  mg/dL.24,25  The  mean  value  of  
adequate calorie and protein intake with BCAA  
substitution was 35-40 kcal/kgBW and protein was  
1.2-1.5 g/kgBW including hepatosol® 2 x 60 g, to reach  
the improvement of nutritional status.12,13 Urea and  
creatinine levels before and after treatment were  
measured to evaluate the side effects on renal 
function.26,27 
The inclusion criteria were liver cirrhosis patients  
with MHE (CFF test < 39 Hz) and malnutrition (MAMC  
below the 15th percentile). Subjects were excluded if  
there was acute infection, gastrointestinal bleeding, and  
creatinine level above 3 mg/dL, concentration  
disturbances and visual impairment. All liver cirrhosis  
patients who meet the inclusion criteria were tested  
for their MAMC and CFF. Blood was taken for  
the examination of prealbumin, albumin, bilirubin,  
prothrombin time, urea, creatinine and ammonia.  
Education was given for adequate calories and  
protein intake. Afterwards, all subjects were given  
LOLA granules (hepamerz®) 3 x 6 g daily for 2 weeks.  
Then their prealbumin and CFF test were measured  
again. Statistical analysis conducted forpre-test  
post-test design was paired T-test or Wilcoxon test. 
RESULTS 
During the period of June - October 2009, we  
obtained 17 liver cirrhosis patients who meet the  
inclusion criteria (table 1). Ninety-four percent  
(16 subjects) were male and there was only 1 female  
patient. The mean age was 53.2 + 11.8 years, most  
subjects had a Child Pugh score B (91.2%). None of  
the subjects complained the side effects of BCAA or  
LOLA. 
Statistical analysis showed that mean value of CFF 
and prealbumin after LOLA and adequate calories and 
protein intake including BCAA was significantly higher 
than before treatment.  
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Table 1. Subject characteristics  
Variable n (%) Mean ± SD 
Sex   
 Male 16 (94.1)  
 Female 1 (5.9)  
Age (years)  53.2 ± 11.8 
Hospital   
 Cipto Mangunkusumo 10 (58.8)  
 Koja 7 (41.2)  
Child Pugh   
 B 15 (88.2)  
 C 2 (11.8)  
Ammonia level (µmol/L)  146.9 (38) 
Urea level (mg/dL)  22.8 (8.4) 
Creatinine level (mg/dL)  0.8 (0.1) 
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DISCUSSION
Result of statistical analysis showed improvement
of CFF after treatment. Such significant improvement
shows that LOLA can reduce plasma ammonia
levels, so that diets with a normal content of protein
can be administered safely to patients with hepatic
encephalopathy.
It also can be seen that the provision of LOLA can
improve MHE, and that the LOLA intake together with
the improvement of nutrition are needed to overcome
MHE on the malnourished liver cirrhosis patients. MHE
improvement with such provision of LOLA is in
accordance with Kircheis study and Poo.14,16
However, study of LOLA in malnutrition liver
cirrhosis with minimal encephalopathy is limited.
In hepatic encephalopathy, protein intake was restricted
in order to decrease blood ammonia level. But low
protein intake could lead to malnutrition, and
malnutrition will worsen the prognosis of liver
cirrhosis.13 Further studies are still needed to provide
information that normal protein intake could be given
in liver cirrhosis with malnutrition, without
aggravation of hepatic encephalopathy.
Adequate calorie and protein on our subjects did
not aggravate MHE, as measured by the CFF. This
shows that the normal protein intake (1.2-1.5 g/kg)
remains safe for MHE. The CFF indicates that the
provision of normal protein may not worsen HE as
proposed in earlier theories.2,28 Normal proteins
that do not aggravate the HE, has been suggested
by previous researchers. Cordoba states that
the normal protein can be given safely in liver
cirrhosis with an episode of acute HE.29 Gheorghe
stated that for improvement of HE, protein restriction
is not necessary.30 The results obtained in our study
reinforce findings from previous researchers.
Results of statistical tests showed that mean
prealbumin level after adequate calorie and protein
intake including BCAA substitution was significantly
higher. The improvement of prealbumin in our study
showed that patients had followed the dietary
guidance. It assumed that patients who took adequate
protein intake had increased blood ammonia level, but
who took LOLAwould have reduced level. Therefore,
no worsening of hepatic encephalopathy was seen.
Results of our study are in accordance with
previous studies, which found that BCAA can improve
the nutritional status of liver cirrhosis patients with
malnutrition.30 Muto and Nakaya have found
improvement of serum albumin level in patients with
advanced cirrhosis.31,32
Prealbumin is used as a parameter of nutrition
improvement because it has a short half-life (2 days),
so it is more sensitive to view changes in calorie-
protein status and more accurately reflects the
nutritional intake of current patient. It is supported by
Beck, Devoto and Shenkin, which state that
prealbumin is a practical examination and can be
relied upon to assess the efficiency of nutritional
intervention.24,25,33
Because LOLA works by stimulating urea cycle,
elevation of blood urea levels can occurs. Therefore,
in our study the safety of LOLA granules to urea and
creatinine levels is evaluated after provision for
2 weeks.
From the mean posttest levels of urea, we obtained
an increase of 4 mg/dL, but such increase was not
clinically significant because it is still below the upper
limit of normal values. In addition, the post-test
creatinine level did not increase compared to the
pre-test value. It strengthens the fact that renal
function was not disrupted even though the production
of urea increased.
CONCLUSION
The results of this study indicated that the mean of
CFF test after giving LOLA with adequate calorie and
protein intake including BCAA substitution are higher
than before treatment. The mean levels of prealbumin
after giving adequate calories and protein intake
including BCAA substitution with LOLA are higher
than before treatment.
Based on the study results, it can be recommended
for patients with MHE and malnutrition to be treated
with LOLA granules for improving their
encephalopathy condition, and they can be given an
adequate calories and protein intake including BCAA
substitution to improve their nutritional status. Further
studies are recommended to ensure the efficiency and
drug side effects, with a better design, larger sample
and longer time.
Table 2. Difference of mean value on CFF, prealbumin, urea, and creatinine level before 
and after treatment 
 Before After Different p† 
(mean ± SD) (mean ± SD) (mean ± SD) 
CFF (Hz) 34.1 ± 2.5 36.5 ± 2.9 2.4 ± 1.6 < 0.001* 
Prealbumin (mg/dL) 5.4 ± 2.1 6.4 ± 2.6 1 ± 1.3 0.008* 
Urea (mg/dL) 22.8 ± 8.4 26.8 ± 7.6 4 ± 4.9 0.06 
Creatinine (mg/dL) 0.8 ± 0.1 0.83 ± 0.1 0.03 ± 0.1 0.8 
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